Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt

American Journal of Physiology - Endocrinology and Metabolism

Volumn 289, Issue 2 52-2, 2005, Pages

  Weigert, Cora ^a   Hennige, Anita M ^a   Brodbeck, Katrin ^a   Häring, Hans U ^a   Schleicher, Erwin D ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Akt; Insulin signaling; Liver; Muscle; Signaling

Indexed keywords

GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3; INSULIN; INTERLEUKIN 6; PROTEIN KINASE B; SERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GLYCOGEN SYNTHESIS; HORMONE ACTION; INSULIN SENSITIVITY; MALE; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TISSUE SPECIFICITY;

ANIMALS; CELLS, CULTURED; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3; HEPATOCYTES; INSULIN; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MUSCLE FIBERS; MUSCLE, SKELETAL; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SERINE; SIGNAL TRANSDUCTION;

EID: 23044499225     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00448.2004     Document Type: Article

References (35)

1. Akira S, Taga T, and Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 54: 1-78, 1993.
2. Bruce CR and Dyck DJ. Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-α. Am J Physiol Endocrinol Metab 287: E616-E621, 2004.
3. Chen RH, Chang MC, Su YH, Tsai YT, and Kuo ML. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J Biol Chem 274: 23013-23019, 1999.
4. Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, and Pedersen BK. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53: 1643-1648, 2004.
5. Febbraio MA and Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 16: 1335-1347, 2002.
6. Febbraio MA, Steensberg A, Keller C, Starkie RL, Nielsen HB, Knistrup P, Ott P, Secher NH, and Pedersen BK. Glucose ingestion attenuates interleukin-6 release from contracting skeletal muscle in humans. J Physiol 549: 607-612, 2003.
7. Fernandez-Real JM, Broch M, Vendrell J, and Ricart W. Insulin resistance, inflammation, and serum fatty acid composition. Diabetes Care 26: 1362-1368, 2003.
8. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, and Ricart W. Circulating interleukin 6 levels, blood pressure, and insulin Sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86: 1154-1159, 2001.
9. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20, 2003.
10. Hennige AM, Burks DJ, Ozcan U, Kulkarni RN, Ye J, Park S, Schubert M, Fisher TL, Dow MA, Leshan R, Zakaria M, Mossa-Basha M, and White MF. Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes. J Clin Invest 112: 1521-1532, 2003.
11. Kanemaki T, Kitade H, Kaibori M, Sakitani K, Hiramatsu Y, Kamiyama Y, Ito S, and Okumura T. Interleukin 1 beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. Hepatology 27: 1296-1303, 1998.
12. Kern PA, Ranganathan S, Li C, Wood L, and Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280: E745-E751, 2001.
13. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, and Kim JK. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53: 1060-1067, 2004.
14. Klover PJ, Zimmers TA, Koniaris LG, and Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52: 2784-2789, 2003.
15. Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E, Roka R, and Schernthaner G. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 23: 1042-1047, 2003.
16. Krutzfeldt J, Kausch C, Volk A, Klein HH, Rett K, Haring HU, and Stumvoll M. Insulin signaling and action in cultured skeletal muscle cells from lean healthy humans with high and low insulin sensitivity. Diabetes 49: 992-998, 2000.
17. Mohamed-Ali V, Good rick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, and Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82: 4196-4200, 1997.
18. Pedersen BK, Steensberg A, Fischer C, Keller C, Keller P, Plomgaard P, Febbraio M, and Saltin B. Searching for the exercise factor: is IL-6 a candidate? J Muscle Res Cell Motil 24: 113-119, 2003.
19. Penkowa M, Keller C, Keller P, Jauffred S, and Pedersen BK. Immunohistochemical detection of interleukin-6 in human skeletal muscle fibers following exercise. FASEB J 17: 2166-2168, 2003.
20. Pickup JC, Mattock MB, Chusney GD, and Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40: 1286-1292, 1997.
21. Pradhan AD, Manson JE, Rifai N, Buring JE, and Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327-334, 2001.
22. Rieusset J, Bouzakri K, Chevillotte E, Ricard N, Jacquet D, Bastard JP, Laville M, and Vidal H. Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 53: 2232-2241, 2004.
23. Rosendal L, Sogaard K, Kjaer M, Sjogaard G, Langberg H, and Kristiansen J. Increase in interstitial interleukin-6 of human skeletal muscle with repetitive low-force exercise. J Appl Physiol 2004.
24. Rotter V, Nagaev I, and Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278: 45777-45784, 2003.
25. Scheid MP and Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 546: 108-112, 2003.
26. Senn JJ, Klover PJ, Nowak IA, and Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51: 3391-3399, 2002.
27. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, and Mooney RA. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278: 13740-13746, 2003.
28. Shulman RG and Rothman DL. The "glycogen shunt" in exercising muscle: A role for glycogen in muscle energetics and fatigue. Proc Natl Acad Sci USA 98: 457-461, 2001.
29. Sopasakis VR, Sandqvist M, Gustafson B, Hammarstedt A, Schmelz M, Yang X, Jansson PA, and Smith U. High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator. Obes Res 12: 454-460, 2004.
30. Staiger H, Kausch C, Guirguis A, Weisser M, Maerker E, Stumvoll M, Lammers R, Machicao F, and Haring HU. Induction of adiponectin gene expression in human myotubes by an adiponectin-containing HEK293 cell culture supernatant. Diabetologia 46: 956-960, 2003.
31. Stouthard JM, Oude Elferink RP, and Sauerwein HP. Interleukin-6 enhances glucose transport in 3T3-L1 adipocytes. Biochem Biophvs Res Commun 220: 241-245, 1996.
32. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, and Chrousos GP. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 82: 4167-4170, 1997.
33. van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA, and Pedersen BK. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88: 3005-3010, 2003.
34. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, and Jansson JO. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8: 75-79, 2002.
35. Weigert C, Brodbeck K, Staiger H, Kausch C, Machicao F, Haring HU, and Schleicher ED. Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteasome-dependent activation of nuclear factor-kappaB. J Biol Chem 279: 23942-23952, 2004.